Budget Impact Analysis of Avelumab in Patients with Metastatic Merkel Cell Carcinoma in The US

Value in Health ◽

10.1016/j.jval.2017.08.153 ◽

2017 ◽

Vol 20 (9) ◽

pp. A424

Author(s):

M Bharmal ◽

SP D'Angelo ◽

H Phatak

Keyword(s):

Cell Carcinoma ◽

Merkel Cell Carcinoma ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Merkel Cell ◽

Download Full-text

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s202642 ◽

2019 ◽

Vol Volume 11 ◽

pp. 349-359 ◽

Author(s):

Murtuza Bharmal ◽

Mairead Kearney ◽

Ying Zheng ◽

Hemant Phatak

Keyword(s):

Cell Carcinoma ◽

Merkel Cell Carcinoma ◽

Budget Impact ◽

Impact Model ◽

Merkel Cell ◽

The Us ◽

Budget Impact Model ◽

Download Full-text

Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US

Journal of Medical Economics ◽

10.1080/13696998.2018.1557199 ◽

2019 ◽

Vol 22 (2) ◽

pp. 187-195 ◽

Author(s):

Lei Wu ◽

Lixian Zhong

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive ◽

Download Full-text

Alemtuzumab Budget Impact Analysis in Relapsing-Remitting Multiple Sclerosis in the US

Value in Health ◽

10.1016/j.jval.2015.03.1637 ◽

2015 ◽

Vol 18 (3) ◽

pp. A280

Author(s):

C. Celestin ◽

T. Wandstrat ◽

C.I. Coleman

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

The Us ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Budget Impact Analysis of Sunitinib Versus Best Supportive Care for The Treatment of Metastatic Renal Cell Carcinoma in Chile

Value in Health ◽

10.1016/j.jval.2016.09.2130 ◽

2016 ◽

Vol 19 (7) ◽

pp. A718

Author(s):

C Vargas ◽

MA Espinoza

Keyword(s):

Renal Cell Carcinoma ◽

Supportive Care ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Impact Analysis ◽

Budget Impact ◽

Best Supportive Care ◽

Budget Impact Analysis

Download Full-text

Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens

Cancer Urology ◽

10.17650/1726-9776-2015-11-2-40-45 ◽

2015 ◽

Vol 11 (2) ◽

pp. 40

Author(s):

A. Yu. Kulikov ◽

Yu. V. Rybchenko

Keyword(s):

Cost Effectiveness ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Impact Analysis ◽

Budget Impact ◽

Transitional Cell ◽

Budget Impact Analysis

Download Full-text

PIN46 VAX-THE-NATION: A BUDGET IMPACT ANALYSIS OF INCREASED MEASLES, MUMPS AND RUBELLA VACCINATION UPTAKE IN THE US

Value in Health ◽

10.1016/j.jval.2019.04.916 ◽

2019 ◽

Vol 22 ◽

pp. S201-S202

Author(s):

C. Painter ◽

T. Curteis ◽

E. Walker ◽

N.C. Hearmon

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Vaccination Uptake ◽

The Us ◽

Rubella Vaccination

Download Full-text

Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.

Journal of Medical Economics ◽

10.1080/13696998.2018.1452510 ◽

2018 ◽

Vol 21 (5) ◽

pp. 542-542

Author(s):

Ws Lane ◽

James Weatherall ◽

Jens Gundgaard ◽

Richard F. Pollock

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Impact Analysis ◽

Budget Impact ◽

Insulin Degludec ◽

Budget Impact Analysis ◽

Download Full-text

HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2019.7474 ◽

2020 ◽

Vol 18 (3.5) ◽

pp. HSR20-096

Author(s):

Frank Xiaoqing Liu ◽

Kirstin Heinrich ◽

Catarina Neves ◽

Ying Zheng ◽

Adam Kasle

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

10.1186/1471-2407-13-399 ◽

2013 ◽

Vol 13 (1) ◽

Author(s):

Guillermo Villa ◽

Luis-Javier Hernández-Pastor

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Budget Impact Analysis of Niraparib and Olaparub As Maintenance Therapy for Platinum Sensitive, Recurrent Ovarian Cancer In The US

Value in Health ◽

10.1016/j.jval.2018.04.132 ◽

2018 ◽

Vol 21 ◽

pp. S22

Author(s):

L Wu ◽

L Zhong

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive ◽

Download Full-text